Cowen & Co. analyst Marc Frahm initiates coverage on Xilio Therapeutics (NASDAQ:XLO) with a Outperform rating.
Cowen & Co. Initiates Coverage On Xilio Therapeutics with Outperform Rating
Cowen & Co. analyst Marc Frahm initiates coverage on Xilio Therapeutics (NASDAQ:XLO) with a Outperform rating.
Related Posts
Mizuho Maintains Buy on PTC, Raises Price Target to $155
Mizuho analyst Matthew Broome maintains PTC (NASDAQ:PTC) with a Buy and raises the price target from $135 to $155.
Telsey Advisory Group Maintains Market Perform on Nordstrom, Raises Price Target to $30
Telsey Advisory Group analyst Dana Telsey maintains Nordstrom (NYSE:JWN) with a Market Perform and raises the price target from $27 to $30.
Analysts See Upto 12% Upside In Carlisle Companies
Baird analyst Timothy Wojs raised Carlisle Companies, Inc’s (NYSE:CSL) price target to $250 from $240 (implying 10% upside) and maintained an Outperform…